Can Treating Depression Mitigate CVD Risk?

Researchers analyzed health insurance claims from more than 4 million Japanese patients filed between 2005 and 2022.
Participants were 18-75 (median age, 44) without a history of CVD or stroke, heart failure, or atrial fibrillation.
Investigators followed participants for a mean period of 2.5-3.5 years to observe the number of CVD events in those who had a diagnosis of depression.
During the follow-up period, there were 119,000 CVD events in men (14 per 10,000 person-years) and 61,800 CVD events in women (111 per 10,000 person-years).

Compared with women without depression, those with depression had a 64% higher risk for CVD (hazard ratio [HR], 1.64), while men with depression had a 39% higher risk for CVD vs their counterparts without depression (HR, 1.39; P < .001).
This association was significant even after controlling for various factors such as body mass index, diabetes, smoking, alcohol consumption, and physical inactivity.
Investigators offered several theories about the increased risk for CVD in women with depression, including how depression during hormonal shifts can contribute to a greater impact on cardiovascular health.

Time-Restricted Eating May Help Adults With Metabolic Syndrome Improve Several Health Markers According to a randomized controlled trial, adults with metabolic syndrome and elevated blood sugar levels who eat for a limited time may experience minor improvements in several indicators, including A1c levels, weight, and body fat.

Impact of multiple obesity metrics on hypertensive disorders of pregnancy: a meta-analysis and Mendelian randomisation study This study demonstrates that various obesity measures are causally linked to increased HDP risk and highlights the mediating role of triglycerides. These findings could inform clinical practices and public health strategies aimed at reducing HDP through targeted obesity and triglyceride management.

Optimal treatment of symptomatic patients with low-gradient severe Aortic valve Stenosis and preserved left ventricular ejection fraction (ROTAS trial) The best management of symptomatic patients with low-gradient (LG) severe aortic stenosis (AS) and preserved left ventricular ejection fraction (LVEF) has not been established.

Cardiovascular safety of vitamin B3 administration Scientists recently reported associations between serum levels of the terminal niacin metabolites N1-methyl-2-pyridone-5-carboxamide (2PY) and N1-methyl-4-pyridone-3-carboxamide (4PY) with an increased 3-year incident risk of major adverse cardiovascular events.

Semaglutide Reduces MACE, Death in Participants With CVD, Overweight/Obesity, and Impaired Kidney Function Semaglutide (Wegovy) prevents major cardiac events including death in adults with overweight/obesity and cardiovascular disease (CVD), both with and without impaired kidney function, a subgroup analysis of the Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) trial shows.

CARDIOPROGRESS
Foundation for the advancement of cardiology